about
Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugsIn Vitro Characterization of the Pharmacological Properties of the Anti-Cancer Chelator, Bp4eT, and Its Phase I MetabolitesMolecular remodeling of left and right ventricular myocardium in chronic anthracycline cardiotoxicity and post-treatment follow up.Comparison of various iron chelators and prochelators as protective agents against cardiomyocyte oxidative injury.Iron is not involved in oxidative stress-mediated cytotoxicity of doxorubicin and bleomycin.Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cellsSimultaneous determination of the novel thiosemicarbazone anti-cancer agent, Bp4eT, and its main phase I metabolites in plasma: application to a pilot pharmacokinetic study in rats.LC-UV/MS methods for the analysis of prochelator-boronyl salicylaldehyde isonicotinoyl hydrazone (BSIH) and its active chelator salicylaldehyde isonicotinoyl hydrazone (SIH)Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: dissection of critical structure-activity relationships.Structure-activity relationships of novel salicylaldehyde isonicotinoyl hydrazone (SIH) analogs: iron chelation, anti-oxidant and cytotoxic properties.Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial InjuryOxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection.Characterization of cytoprotective and toxic properties of iron chelator SIH, prochelator BSIH and their degradation products.Dexrazoxane-afforded protection against chronic anthracycline cardiotoxicity in vivo: effective rescue of cardiomyocytes from apoptotic cell deathAre cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?Cardioprotective effects of iron chelator HAPI and ROS-activated boronate prochelator BHAPI against catecholamine-induced oxidative cellular injuryAroylhydrazone iron chelators: Tuning antioxidant and antiproliferative properties by hydrazide modifications.Intravenous rutin in rat exacerbates isoprenaline-induced cardiotoxicity likely due to intracellular oxidative stress.Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model.Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.Comparison of various iron chelators used in clinical practice as protecting agents against catecholamine-induced oxidative injury and cardiotoxicity.Iron chelation with salicylaldehyde isonicotinoyl hydrazone protects against catecholamine autoxidation and cardiotoxicity.Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury.Direct administration of rutin does not protect against catecholamine cardiotoxicity.Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.Cardioprotective effects of inorganic nitrate/nitrite in chronic anthracycline cardiotoxicity: Comparison with dexrazoxane.SIH--a novel lipophilic iron chelator--protects H9c2 cardiomyoblasts from oxidative stress-induced mitochondrial injury and cell death.Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.Tetra(3,4-pyrido)porphyrazines Caught in the Cationic Cage: Toward Nanomolar Active Photosensitizers.Water-soluble non-aggregating zinc phthalocyanine and in vitro studies for photodynamic therapy.Far-red-absorbing cationic phthalocyanine photosensitizers: synthesis and evaluation of the photodynamic anticancer activity and the mode of cell death induction.Comparative study of chronic toxic effects of daunorubicin and doxorubicin in rabbits.Cardiac troponin T as an indicator of reduced left ventricular contractility in experimental anthracycline-induced cardiomyopathy.Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits.Cardioprotective potential of iron chelators and prochelators.Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits.Pyridoxal isonicotinoyl hydrazone (PIH) and its analogs as protectants against anthracycline-induced cardiotoxicity.Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.Proteomic insights into chronic anthracycline cardiotoxicity.Corrigendum to: "Proteomic investigation of embryonic rat heart-derived H9c2 cell line sheds new light on the molecular phenotype of the popular cell model" [Exp. Cell Res. 339 2 (2015) 174-186].
P50
Q28539989-F837D70F-6E30-4449-8324-BA2B374A9D9DQ28550205-512958A3-673A-481D-94B0-08E0A76C45B5Q33578496-5C88CB1E-9A7E-4EC8-B56D-7E1CDD248FE4Q34568034-11BE007A-2D9D-4E84-8A92-C93572DE0D0DQ34571662-763370BD-CB6E-46E2-AEC1-39D183333287Q35014803-DDF61E65-81C1-4195-B5B7-B94298E826E5Q35047321-27572F5A-0AAA-4BED-B7CC-8DA67524DD0BQ35071893-3E290753-CBFF-4A2A-8ECE-52766DF94B73Q35348485-E4D6172E-BE90-483A-8FD5-0B4C5881C280Q35418008-5112E92B-10BC-4B78-8CB1-3A00079A768DQ36405689-A39986BD-C24D-4F1C-B2DB-15298BC29642Q36568908-B56D8BCF-B67D-491A-8B3A-3E8E20946F29Q36957543-6516C035-F483-4597-877D-2C1A724F233BQ37330749-3F377DA6-1EE2-4371-A8D4-DDC8728F0B7CQ38732745-FA2E1D64-3F6D-4F35-9B2F-AA11AB8081ABQ38741123-09529BF2-CC2C-4997-B3E1-E3974652DC31Q38770392-708DA0B0-5948-459E-B6DD-4B7A52B5CA7CQ38778332-3F51EF48-7294-4CA3-B832-733986876490Q38823791-75D02DBD-8E6F-47AB-8AF2-5CD936E7D0A6Q39361260-C4EF0E02-5F77-47C0-836A-F06F39D1AD88Q39485305-667A8EC2-8F6A-4F17-85BA-182BD2A40F21Q39621619-B8BE4197-CB8C-490D-A8BC-A32FFD7FDCABQ39696938-E33BF2D4-DD4C-49D2-A8F1-09209C1502B7Q39920006-3513B481-9B3D-471F-A958-7838E41900E2Q39988639-D0CC6E6E-7A39-4BDB-A2B1-763C3313A121Q40151835-8FEAC60C-0B60-4841-BBEF-AE4C89B9EB7BQ40405076-79C7D38A-A3E7-421E-BD42-9594E7D34A59Q42710370-8693C59D-8E34-4016-8B73-09FB768BDD5EQ42807073-1282E98E-D1E0-4D35-AB53-E86D71515B0DQ42813321-3CB3C8C5-BDF3-4D0F-91F5-53423E3895ECQ42831195-4D558D1C-A293-43D6-B1F8-CB53A9209D57Q44286072-14CC32A1-C3F9-4B90-87C2-FC84A85D8F3EQ44656206-A63628E0-D800-4456-B077-E2552AE45B01Q45231768-163D6421-501F-43AE-BB54-3A8B4010044EQ46303582-15114DB1-88EE-43ED-81A4-5DC5C0AB2016Q46545274-FEB36A64-DEBE-405D-B315-83DC6201137BQ46753895-B6D895CB-6019-407A-B036-E54CE4060705Q54295529-DA8E781B-1DF2-4D2D-BBB4-1DA91F15ADB5Q54389872-03EFB7A5-7FC1-476C-8676-2F7A3B9A78FFQ54549680-8B0AA0DE-1D57-446D-B593-B4E921327530
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Tomas Simunek
@ast
Tomas Simunek
@en
Tomas Simunek
@es
Tomas Simunek
@nl
Tomas Simunek
@sl
type
label
Tomas Simunek
@ast
Tomas Simunek
@en
Tomas Simunek
@es
Tomas Simunek
@nl
Tomas Simunek
@sl
prefLabel
Tomas Simunek
@ast
Tomas Simunek
@en
Tomas Simunek
@es
Tomas Simunek
@nl
Tomas Simunek
@sl
P1053
A-3938-2008
P106
P21
P31
P3829
P496
0000-0001-5464-4176